The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Introduction/Overview
T2DM as a Risk Factor for CVD
Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review
Mechanisms Associating Type 2 Diabetes and Cardiovascular Disease
Shorter-, Longer-Acting GLP-1 RAs: Compositional Differences and Comparative Clinical Trial Data
Molecular Structure: GLP-1, Liraglutide, Dulaglutide, Albiglutide, Exenatide, Lixisenatide, and Semaglutide
Results From SUSTAIN 1-5 (Semaglutide): Change in HbA1c
SUSTAIN 7: Changes in HbA1c and Body Weight, Semaglutide vs Dulaglutide
ELIXA: Primary Outcome: CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for Unstable Angina
Primary Endpoint Results From the LEADER Trial*
HARMONY OUTCOMES Primary Endpoint Results: Time to CV Death, MI or Stroke (MACE)
SUSTAIN-6 (Semaglutide): Primary Outcome Results
Dulaglutide’s Effect on the CV Composite Primary Outcome: First Occurrence of Nonfatal MI, Nonfatal Stroke, CV Death
Difference in CVOT Design: Patient Populations (Inclusion Criteria and Baseline Characteristics
CVOT Trials: Differences in Cardiovascular Risk
REWIND Results: CV Composite in Prespecified Subgroups
GLP-1 RAs and Experimental Models of CVD
Patient Preferences: Injection vs Increased Urinary Frequency
Sodium Salcaprozate (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) Oral Absorption Promoter
PIONEER 1, 2, 3, 4, and 7: Change in HbA1c
PIONEER Clinical Development Program
PIONEER 1,5,8: Body Weight Change From Baseline: Oral Semaglutide vs Liraglutide
PIONEER 4: Estimated Mean Change From Baseline in HbA1c Oral Semaglutide vs SC Liraglutide
Will an Oral GLP-1 RA Change the Treatment Paradigm?
How Big a Problem Is Needle Phobia?
Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations
Patient Selection With Cardiorenal Protective Glucose-Lowering Agents
Decision Cycle for Patient-Centered Glycemic Management in Type 2 Diabetes
Summary and Conclusions
Abbreviations
Abbreviations (cont)